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IL-I is a multipotent inflammatory mediator that may play a central role in
vascular pathophysiology. For example, IL-1 promotes the adhesion ofall classes
of leukocytes to cultured endothelial cells (1-3) and increases their production
of procoagulant activity (4), plasminogen activator inhibitor (5, 6), and prosta-
glandins (7, 8). These actions of IL-1 indicate its importance in mediating
disturbances of endothelial function associated with vascular injury and inflam-
mation. However, there is scant information regarding possible effects of IL-1
on vascular smooth muscle cells, the most abundant cell type in most vessels.
Vascular wall cells are not only targets for the action of IL-1, but can also
produce IL-1-like molecules. Two distinct genes encode forms of IL-1 with
similar biological activities but disparate amino acid sequences: IL-la has an
isoelectric point of 5, and IL-1/3 (the predominant form produced by human
monocytes) has an isoelectric point of 7 (9, 10). Recently, we have described the
inducible expression of both of these IL-1 genes in endothelial cells and smooth
muscle cells cultured from adult human blood vessels (I 1-13). In these cell types,
bacterial endotoxins and recombinant human tumor necrosis factor/cachectin
(rTNF)' induced the appearance of IL-10 messenger RNA (mRNA) and release
of IL-I. We now report that IL-1 itself is a potent stimulus for IL-1 gene
expression in vascular smooth muscle cells from adult humans. The demonstra-
tion that smooth muscle is both a source of IL-I and a target for this cytokine
raises the possibility ofnovel feedback loops in vascular pathophysiology. These
findings expand the known responses of vascular smooth muscle cells, and also
broaden the scope of the actions of the IL-1 polypeptides on the blood vessel
wall.
Materials and Methods
Cell Culture. Human saphenous vein smooth muscle cells (HSVSMC) were isolated
from outgrowths of explants of unused portions of veins harvested for coronary artery
bypass surgery. The endothelium was removed enzymatically, and the adventitia was
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removed by blunt and sharp dissection before culture of the explants (12). This use of
normally discarded tissues was approved by the Human Investigation Review Committee
of New England Medical Center, Boston, MA. Human aortic and iliac arterial smooth
muscle cells were prepared by enzymatic dissociation from tissues obtained from organ
donors, with the cooperation of the New England Organ Bank. The adventitia and
abluminal portions of the tunica media were removed before dissociation of the tissue
with collagenase (CLS III, 0.2%; Cooper Biomedical, Inc., Malvern, PA). The cells were
maintained in DME that contained glucose (5.5 mM), Hepes (25 mM), and FCS (HyClone
Laboratories, Logan, UT) (10%). The morphology and growth pattern of the cells
determined by phase-contrast microscopy were typical of cultured smooth muscle cells
(14, 15). Cultures were used in the third to eighth passage.
Reagents. Phenol-extracted LPS from Escherichia coli 0111 :114 was obtained from
Sigma Chemical Co., St. Louis, MO, and further purified by enzymatic digestion of
contaminating protein and nucleic acid, followed by chromatography on Sepharose 411,
as previously described (16, 17). Recombinant human IL-1/3 (rIL-1,B) (18), affinity-purified
human monocyte IL-1 (19), and rabbit antisera to semipurified human monocyte IL-1
(20) and to rTNF (21) were provided by Dr. Charles A. Dinarello of Tufts University.
Recombinant human IL-la (rIL-la) (22) was obtained from Dr. Peter T. Lomedico of
Hoffmann-LaRoche, Inc., Nutley, NJ. mAb to the monocyte antigen Mot (23, 24) was a
gift from Dr. Stuart F. Schlossman of the Dana Farber Cancer Institute, Boston, MA.
Polymyxin B and indomethacin were purchased from Sigma Chemical Co.
Isolation of RNA and Northern Analysis.
￿
Cultured cells were detached by treatment
with trypsin (0 .25%, TRL 111; Cooper Biomedical, Inc.) in EDTA (0.05%) and lysed in
guanidine isothiocyanate (4 M). RNA was pelleted by centrifugation through cesium
chloride cushions (25, 26). The concentration of RNA was determined from the absorb-
ance at 260 nm, and A260/A2ao ratios were >2 . RNA was electrophoresed in agarose gels
(1 .2%) containing formaldehyde (2.2 M) (27). After capillary transfer of the RNA to
nylon membranes (Hybond-N; Amersham Corp., Arlington Heights, IL), the RNA was
immobilized by shortwave UV illumination for 3 min on each side of the membrane. The
membranes were prehybridized for at least 4 h before hybridization with the s2P-labeled
probes described below (27). Autoradiography was carried out for 1-5 d using Kodak X-
Omat AR-5 film with intensification screens (Eastman Kodak Co., Rochester, NY).
Densitometry of autoradiograms was performed with an LKB 2202 Ultroscan laser
densitometer and LKB 2220 recording integrator (LKB Produkter AB, Bromma, Swe-
den).
DNA Probes.
￿
IL-1,8 was detected using a fragment (positions 278-1,381) of IL-1,0
cDNA isolated from pGEM-IL-1,8 (11). Drs. Philip E. Auron, C. A. Dinarello, and S. M.
Wolffof the Department of Medicine, Tufts University, provided pCD 411 from which
pGEM-IL-1,Qwas constructed (28)./3-Tubulin was detected using a fragment (1 kb) of rat
cDNA obtained from RBT.3 (29), a gift of Dr. Stephen R. Farmer of the Department of
Biochemistry, Boston University. IL-la was detected using a synthetic oligonucleotide
(positions 298-339) synthesized by Dr. Richard Malavarca of Cistron Technology, Inc.,
Pine Brook, NJ, and acDNA probe isolated from pA3 IL-la, obtained from Dr. Peter T.
Lomedico. This construct contains the complete coding region for amino acids 1-132
(cDNA positions 1-432) of the 33-kD IL-la precursor. Plasmids were isolated chromat-
ographically (30). Inserts were isolated after restriction endonuclease digestion by low-
melt agarose gel electrophoresis or electroelution, and labeled by nick translation with
[32P]dCTP and [
s2P]dGTP (3,000 Ci/mmol; New England Nuclear, Boston, MA) (27).
The oligonucleotide was end-labeled with 1'-[32P]ATP (27). The specific activity of the
probes was >I0' cpm/Ng DNA.
Assay of IL-1 Biological Activity.
￿
Medium collected from cultures of HSVSMC (condi-
tioned medium) was centrifuged (10 min at 1,000g) and stored at -70°C until assay. For
determination of intracellular IL-1, cell layers were washed three timeswith DME, covered
with I ml of FCS (5%) in RPMI 1640 medium, and frozen at -20°C. After thawing, the
plates were scraped with a rubber policeman and the lysate was centrifuged (15 min at
1,000 g), and the supernatants were stored at -70°C until assay. IL-1 activity was1318 VASCULAR SMOOTH MUSCLE CELL INTERLEUKIN 1 PRODUCTION
determined by the murine thymocyte costimulation assay (31). At least two dilutions (1 :1
and 1 :10) of test samples were incubated in 96-well plates (Costar, Inc., Cambridge, MA)
with 5 X 105 thymocytes from C3H/Hej mice (6-8 wk old; The Jackson Laboratory, Bar
Harbor, ME) in a final volume of 200 A1 of RPMI 1640 containing FCS (5%), PHA (1
gg/ml; Burroughs Wellcome, Research Triangle Park, NC), antibiotics, glutamine (2 mM),
and 2-ME (5 X 10-5 M). Affinity-purified human monocyte IL-1 was included in each
assay as a positive control. After 48 h, ['H]thymidine (1 pCi/well, 20 or 6.7 Ci/mmol;
New England Nuclear) was added to the wells, and cells were harvested 18-24 h later
onto glass fiber filters using a commercial cell harvester (Cambridge Technology, Cam-
bridge, MA). The filters were counted in Econosolve HP/b scintillation fluid (Beckman
Instruments, Inc., Palo Alto, CA), and quench corrections were performed by use of an
external standard. The results are reported as the mean ± standard deviation of disinte-
grations per minute determined on triplicate cultures. Because conditioned medium
contained the rIL-1 used to stimulate smooth muscle cells, as well as IL-1 produced by
these cells, both unconditioned and conditioned media were assayed. Smooth muscle cell
IL-1 production is the difference between IL-1 activity in conditioned medium (HSVSMC-
derived IL-I + rIL-1) and IL-1 in unconditioned medium (rIL-1 alone).
PGE2 Assay.
￿
HSVSMC were cultured in 24-well dishes (Costar) in 1 ml of DME/10%
FCS. The cells were incubated for 1-24 h in the presence or absence of indomethacin (1
wg/ml) and rIL-10 (100 ng/ml). The medium was centrifuged (1,000 g for 15 min),
acidified with HCl (final pH 3), and extracted with 3 vol of ethyl acetate. The organic
phase was dried, and the residue was resuspended in phosphate buffer and assayed for
PGE2 using an RIA kit, according to the manufacturer's instructions (Seragen Inc.,
Boston, MA).
Endotoxin Determination.
￿
Levels of bacterial endotoxin in tissue culture media were
determined with the use of the chromogenic limulus lysate assay (QCL 1000, M. A.
Bioproducts, Walkersville, MD). This assay is sensitive to 10 pg/ml of bacterial endotoxin.
Very low concentrations of bacterial endotoxin (<1 ng/ml) can induce IL-1,8 gene product
in human vascular smooth muscle cells (12, and data not shown). In some cases we have
found IL-10 mRNA in HSVSMC not deliberately exposed to endotoxin, and have
subsequently measured concentrations of endotoxin >100 pg/ml in the tissue culture
media. Basal IL-1 production by HSVSMC could be avoided by culturing cells in medium
selected for low levels of endotoxin contamination (<40 pg/ml). In addition, the experi-
ments reported here were routinely carried out in the presence ofthe endotoxin antagonist
polymyxin B (10 Pg/ml).
Treatment of Cells with Antimonocyte Antibody and Complement.
￿
To test whether IL-1
production by HSVSMC might be due to contamination with blood monocytes, cultures
were treated with mAb to the monocyte antigen Mo2 (anti-Mo2)and complement, before
stimulation with LPS or rIL-1 . The cells were incubated with anti-Mo2 (1 :150 dilution
in DME/10% heat-inactivated FCS), or medium without the antibody, for 30 min at 4° C.
The medium was aspirated and replaced with a 1 :4 dilution of baby rabbit complement
(Pel-Freez Biologicals, Rogers, AK). After incubation for 1 h at 37°C the cells were
washed three times with HBSS and cultured for 24 h in DME/10% FCS. In independent
experiments, such treatment completely lysed adherent human peripheral blood mono-
nuclear cells, as judged by phase-contrast microscopy. The HSVSMC were then incubated
for 6 h in fresh medium containing LPS (1 lAg/ml), or for 24 h with rIL-la (10 ng/ml) or
rIL-1,0 (100 ng/ml). IL-1 was measured in unconditioned and conditioned media, and IL-
10 mRNA was measured by Northern analysis.
Results
IL-1 Induces IL-1 Gene Expression in Human Vascular Smooth Muscle
Cells. Under basal conditions, HSVSMC cultured in low-endotoxin medium
(<40 pg/ml) contained no rnRNA for IL-10. Highly purified IL-1 from human
monocytes induced a concentration-dependent increase in IL-1(0 mRNA levels
(Fig. 1) . Monocyte-derived IL-1 concomitantly induced release by HSVSMC ofWARNER ET AL .
￿
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FIGURE 1 . Human monocyte-derived IL-1 induces IL-lß
mRNA in human vascular smooth muscle cells . HSVSMC were
incubated for 4 h with human monocyte-derived IL-1 diluted
1 :100 and 1:500 in DME/10% FCS containing polymyxin B(10
t~/ml) . Northern analysis of total cellular RNA (20 kg) used a
"P-labeled IL-lß cDNA probe . Arrows indicate position of 288
and 18S ribosomal subunits in this and subsequent figures . The
activity of the monocyte IL-1 in the thymocyte costimulation
assay, measured as [sH]thymidine incorporation (mean dpm ±
SD oftriplicate wells) was 36,823± 2,401 for IL-1 diluted 1:100
and 18,604 ± 380 for IL-1 diluted 1 :500 (both significantly
different from PHAbackground whichwas 15,571 ± 515 dpm,
p < 0.01, Student's t test).
biologically active IL-1, determined as thymocyte costimulation activity (data not
shown) .
This monocyte-derived IL-1 containeda mixture of both the neutral andacidic
IL-I species (20) . rIL-1a and rIL-10 are homogeneous preparations that express
the biological activities of the corresponding monocyte-derived IL-1 species (18,
22) . rIL-10 (0.01-100 ng/ml) caused a concentration-dependent increase in IL-
10 mRNA levels (Fig . 2A) and secretion of IL-1 (Fig . 2B), with a threshold
between 100 pg/ml and 1 ng/ml. The increase in IL-1 mRNA was selective, in
that levels of 0-tubulinmRNA were not altered substantially by rIL-10 (Fig . 2B) .
rIL-1a (0.01-50 ng/ml) also induced IL-10 mRNA in these cells as well as the
release of thymocyte costimulation activity (data not shown) . rIL-1a was more
potent than IL-lß as an inducer of IL-1 production by HSVSMC, in parallel
with an increased potency in the murine thymocyte costimulation assay . This
differential potency between the two species of recombinant IL-1 may be due,
at least in part, to the sensitivity of rIL-10 to oxidation of sulfhydryl groups
associated with a loss of biological activity . The response of smooth muscle
cultures to IL-1 was not limited to venous or explant-derived cells. Arterial
smooth muscle cells isolated by enzymatic dissociation from human aorta or iliac
artery responded to HL-la and rIL-10 in the same manner as cells isolated from
saphenous vein (data not shown) .
HSVSMC treated with HL-Ice or rIL-lß did not contain mRNA for IL-la,1320 VASCULAR SMOOTH MUSCLE CELL INTERLEUKIN 1 PRODUCTION
FIGURE 2 .
￿
Concentration dependence of rIL-Ip-induced production of IL-I,# mRNA and
IL-I activity . HSVSMC were incubated for 4 h with rIL-I# in DME/10% FCS containing
polymyxin B (10 wg/ml) . RNA (20 jug) isolated from the monocytoid cell line U937 (U937)
stimulated for 24 h with LPS (I jug/ml) wasanalyzed simultaneously . ThemRNA transcripts
from HSVSMC comigrate with U937 IL-1,8 mRNA transcripts (1 .6 kb) . (A) Autoradiogram
of Northern analysis. (Tofu) Northern analysis and hybridization with IL-IS probe was per-
formed as in Fig. 1 . (Bottom) The same blot was rehybridized with 12P-labeled rat S-tubulin
probe, and shows approximately equal amounts of hybridization in each lane, indicating that
the RNA in each lane is intact . (B) IL-1 activity. Conditioned (dark bars) and unconditioned
(light bars) media from the same experiment shown in A were assayed (1 :10 dilution) in the
mouse thymocyte costimulation assay . In this and subsequent figures, data are [sH]thymidine
incorporation (mean dpm ± SD, triplicate wells) corrected by subtraction of [sH]thymidine
incorporation in the presence ofPHA alone (In this experiment, 35,223 ± 4,441 dpm) .
determined by using both an end-labeled 32P-synthetic oligonucleotide (42-mer)
probe and a 32P-labeled cDNA probe (data not shown) . Under the same hybrid-
ization conditions, these probes did detect IL-1a transcripts in RNA from LPS-
stimulated human monocytes . We have only observed IL-la mRNA in smooth
muscle cells treated with cycloheximide alone (1 ug/ml) or with rIL-1 and
cycloheximide (data not shown) . This result is in accord with our previous findingWARNER ET AL .
￿
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FIGURE 3 .
￿
Time courseof humanrIL-I-induced IL-
I# mRNA synthesis in HSVSMC . HSVSMC were
incubated in DME/10% FCScontaining polymyxin B
(10 t+g/ml) with rIL-Iß (100 ng/ml, top) or rIL-la (10
ng/ml, bottom) for the time periods indicated . The
incubation with IL-la included indomethacin (I
tag/ml) . RNA (20 tag) was electrophoresed, transferred
to anylon membrane,and hybridized with s2P-labeled
IL-10 probe .
(12) that IL-la mRNA appears in HSVSMC exposed to cycloheximide alone,
and that the LPS-induced increase in IL-1 mRNA levels is augmented by this
inhibitor . Using less stringent washing conditions (1X SSC ; 55°C) we have
detected IL-la mRNA in rIL-l-stimulated HSVSMC (data not shown) .
Induction of IL-1 by rIL-I Is Rapid, Transient, and Dependent on RNA Synthe-
sis . Exposure to rIL-lß (100 ng/ml) increased IL-lßmRNA in HSVSMC within
1 h (Fig . 3, top) . Theamount ofIL-lßmRNA was maximal after 4 h of incubation,
and declined after 24 h of continued exposure to rIL- lß . The time course of the
appearance of IL-lß mRNA induced by rIL-la (10 ng/ml) paralleled that found
in response to rIL-lß (Fig . 3, bottom) . In further experiments using shorter
incubation times, IL-lß mRNA appeared as early as 30 min after exposure to
rIL-1ß (data not shown) . Incubation of HSVSMC for 4 h simultaneously with
the RNA synthesis inhibitor actinomycin D (1 jug/ml) and AL-10 (100 ng/ml)
inhibited the effect of rIL-lß on IL-lß mRNA levels by 99%, measured by
scanning densitometry of an autoradiogram of Northern blot analysis . This
concentration ofactinomycinD inhibited [sH]uridine incorporation by HSVSMC
into material insoluble in perchloric acid (0 .2 M) by 93% (datanot shown) . These
results suggest that rIL-I affects IL-1,QmRNA levels by increasingRNAsynthesis .
The synthesis of IL-l,ß mRNA resulted in the release of biologically active IL-
1 (Fig . 4) . Extracellular IL-1 activity, in excess of that due to the stimulus alone,
rose after 1 h of exposure to rIL-10, continued to increase for up to 8 h, and
declined by 24 h (Fig . 4A). This pattern suggested that the smooth muscle cells
produce an inhibitor of the thymocyte costimulating ability of IL-1, as do
endothelial cells (32) . rIL-la (10 ng/ml) induced a similar time course of IL-1
release, except that IL-1 activity was not decreased at 24 h (Fig . 4B) . The
cyclooxygenase inhibitor indomethacin was included in the incubation medium
in this latter experiment . Preliminary studies had indicated that indomethacin
increased the amount of IL-1 activity measured in conditioned medium from1322 VASCULAR SMOOTH MUSCLE CELL INTERLEUKIN 1 PRODUCTION
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FIGURE 4 .
￿
Time course of IL-1 release fromHSVSMC induced by rIL-1 . IL-1 in conditioned
media (1 :10 dilution) from the same experiments shown in Fig. 3 were measured in the
thymocyte costimulation assay . (A) HSVSMC stimulated with rIL-1ß (100 ng/ml) . (B)HSVSMC
stimulated with rIL-la (10 ng/ml), in the presence of indomethacin (1 Ag/ml) . ['H]-Thymidine
incorporation in response to PHA alone has been subtracted, and was 35,223 ± 4,441 dpm
for the experiment with rIL-10 and 14,149 ± 1,508 dpm for that with rIL-la . Data at zero
time represent [sH]thymidine incorporation in response to unconditioned medium containing
HL-1 alone .
FIGURE 5 . PGE2 production by HSVSMC .
Cells were incubated for the indicated times in
24-well dishes containing DME/10% FCS with
or without rIL-lß (100 ng/ml) and indometh-
acin (1 fag/ml) . PGE2 in the conditioned me-
dium was measured by RIA . Data are mean t
SD of determinations on triplicate wells .
LPS-stimulated HSVSMC . Prostaglandins, in particular PGE2, can suppress the
response of thymocytes to IL-1 (33), and we postulated that the decreased IL-1
activity in conditioned medium after 24 h was due to accumulated PGE2 .
rIL-1 StimulatesPGE2 Production byHSVSMC .
￿
We therefore determined PGE2
levels in the supernatants of HSVSMC exposed to medium alone or to rIL-1ß .
rIL-10 (100 ng/ml) stimulated PGE2 production in a time-dependent manner .
Indomethacin (1 ug/ml) prevented this effect (Fig . 5) . In addition, conditioned
medium from indomethacin-treated cells displayed more IL-1 activity than
medium from cells incubated without the inhibitor (Fig . 6) . Indomethacin alone
did not affect the activity of rIL-lß in the murine thymocyte costimulation assay
(Fig . 6), nor did it affect IL-Iß mRNA levels in HSVSMC . Laser scanning
densitometry of the autoradiogram of a Northern blot hybridized with IL-1ß
probe yielded 1.28 ± 0.01 arbitrary units (U) for HSVSMC exposed to IL-1ß
alone, and 1 .20 ± 0.14 U for cells incubated with rIL-10 and indomethacin
(mean ±SD of threescans at separate positions of each band) . These data suggest
that rIL-l-stimulated HSVSMC producePGE2 , which inhibits the responsivenessWARNER ET AL .
￿
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FIGURE 6.
￿
Effect of indomethacin on IL-1 pro-
duction by HSVSMC . Cellswere incubated for 24
h in DME/10% FCS containing polymyxin B (10
lag/ml) and rIL-ls (100 ng/ml), with or without
indomethacin (1 lag/ml). Unconditioned and con-
ditioned media (1 :1 dilution) were assayed for IL-
1 . [sH]Thymidine incorporation in response to
PHA alone has been subtracted and was 16,257±
2,004dpmformedium without indomethacin, and
16,326 t 862 dpm for medium containing indo-
methacin.
FIGURE 7 . Intra- and extracellular IL-1 in HSVSMC stimulated with HL-10 . Cells were
grown in 60-mm culture dishes and stimulated for the indicated time periods with rIL-10 (100
ng/ml) in 3 ml ofDME/10% FCS containing polymyxin B (10 tag/ml), with (B) or without (A)
indomethacin (1 tag/ml) . Conditioned medium was aspirated and the monolayer was washed
with medium without rIL-1 and freeze-thawed in 1 ml ofRPMI/5% FCS . Intracellular (dark
bars) and extracellular (light bars) IL-1 were determined in the murine thymocyte costimulation
assay (1 :10 dilution) . [sH]Thymidine incorporation in the presence of PHA alone has been
subtracted, and was 10,550± 524dpm formedium without indomethacin, and 11,615 ± 931
dpm for medium with indomethacin .
of thymocytes to IL-1 . Alternatively, indomethacin may decrease the synthesis
ofa specific IL-1 inhibitor.
rIL-1 Induces Intracellular IL-1 Synthesis and Extracellular IL-1 Release.
￿
The
intracellular synthesis and extracellular release of IL-1 by phagocytic leukocytes
are temporally distinct and stimulus specific (34) . We therefore studied the
kinetics of the appearance of intra- and extracellular IL-1 in HSVSMC exposed
to rIL-1,Q. In theabsence ofindomethacin, rIL-1,8(100 ng/ml)producedmaximal
levels of intracellular IL-1 after 6 h that decreased by 24 h(Fig. 7A) . Extracellular
IL-1 levels followed a similar time course . In parallel experiments with the same
isolate of cells, indomethacin (1 ug/ml) did not alter the pattern of appearance
of intracellular IL-1 activity, but caused extracellular IL- I activity to continue to
increase over a 24-h period (Fig . 7B). In addition, indomethacin increased the
amount of intra- and extracellular IL-I activity, as described above (note the
difference in the scale of the ordinates in Fig. 7, A and B) . These kinetic data
suggest that HSVSMC respond rapidly to human IL-1 by synthesizing IL-1(3
mRNA (peak at 4 h), followed by intracellular IL-1 synthesis (peak at 6 h) and
the release of IL-1 . rIL-1 also induces release of PGE2 more slowly (peak >_ 241324 VASCULAR SMOOTH MUSCLE CELL INTERLEUKIN I PRODUCTION
FIGURE 8 .
￿
Inhibition of AL-10-induced IL-1
production by HSVSMC by anti-IL-1 anti-
serum and heat treatment, but not by poly-
myxin B. HSVSMC were incubated for 4 h in
DME/10% FCS containing indomethacin (1
wg/ml) and rIL-1,Q (10 ng/ml) or purified bac-
terial LPS (endotoxin, 10 ng/ml) . Polymyxin B
(PB, 10 Pg/ml) was included where indicated .
Heated endotoxin and rIL-1 were incubated at
95'C for 1 h . Rabbit antiserum to humanmon-
ocyte-derived IL-1 (anti-IL-1) or nonimmune
rabbit serum (NRS) was included at a final
dilution of 1 :100 . Conditioned and uncondi-
tioned media (1:10 final dilution) were assayed
in the murine thymocyte costimulation assay .
Data are [sH]thymidine incorporation (mean ±
SD, triplicate wells) in response to conditioned
media, corrected by subtraction of incorpora-
tion due to the corresponding unconditioned
medium (13,596 ± 1,016 dpm for medium
alone, and 20,182 f 793 dpm for medium
containing rIL-1) .
h), which masks measurable IL-1 activity in conditioned medium from later time
points .
Induction of IL-1 Gene Product by rIL-10 Is Not Due to Endotoxin Contamina-
tion . HSVSMC respond to endotoxin concentrations <1 ng/ml by producing
IL-10 mRNA and releasing IL-1 (12) . The terms endotoxin and LPS are not
synonomous, although most of the endotoxic properties of Gram-negative bac-
terial extracts are due to the LPS component (35) . Here, we use endotoxin to
refer to uncharacterized bacterial products, andLPS to designate a well-charac-
terized, purified preparation. Although the endotoxin content of the rIL-1 used
in this study was in the picogram per milligram range (18), we used several
approaches to exclude the possibility that rIL-1-induced IL-1 synthesis in
HSVSMC might be due to bacterial endotoxin in tissue culture media or IL-1
preparations .
Smooth muscle cells were incubated for 4 h with rIL-1,0 or purified LPS (10
ng/ml each), either alone or with the addition of the LPS antagonist polymyxin
B (10 vg/ml), or rabbit anti-IL-1 antiserum (1 :100 final dilution) . IL-1 release
(Fig . 8) and IL-1,Q mRNA (data notshown) were measured . PolymyxinB blocked
the ability of purified LPS to increase IL-1,0 mRNA levels and IL-1 release but
did not affect this activity ofrIL-1 (3 . Polymyxin B does not inhibit all endotoxins,
however (36), and we used a rabbit antiserum to human monocyte IL-1 to
confirm the specificity of the response of HSVSMC to rIL-I0 . Antiserum to
monocyte IL-1 blocked theproduction ofIL-10mRNA and IL-1 release induced
by rIL-10 but not by LPS. Furthermore, incubating rIL-10 for 1 h at 95°C
destroyed its ability to increase IL-1,0 mRNA levels and IL-1 release, whereas
LPS was unaffected by such heat treatment . These data indicate that rIL-1-
induced IL-1 production by HSVSMC is not an artifact of endotoxin contami-
nation .
IL-1 Production by HSVSMC Is Not Due to Contamination by Blood Mono-
cytes .
￿
Blood monocytes, the prototypical source of IL-1, are potential contami-WARNER ET AL.
￿
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TABLE I
Effect ofTreatmentwith Antimonocyte Antibody and Complement on
IL-1 Production by HSVSMC
Cellswere treated with to withoutantibody to Mo2andthen incubatedwith baby rabbitcomplement
as described in Materials and Methods. IL-1 activity in 1:1 dilutions of unconditioned and
conditioned media is reported as mean ± SD of ['H]TdR incorporation in triplicate cultures in the
thyraocyte costimulation assay.
* Not significantly different from cellstreated with complement alone, p >- 0.08.
$ Not significantly different from corresponding value forrIL-1#, p >_ 0.325, Student's ttest.
nants of blood vessel-derived cell cultures (37) . Our primary smooth muscle cell
cultures were used in thethird or subsequent passage, by whichtime any surviving
monocytes should have acquired macrophage-like characteristics. This differen-
tiation is associated with loss of the ability to secrete IL-1 (35). Nonetheless, we
addressed this possibility directly by treating HSVSMC sequentially with mAb to
the human monocyte antigen Mo2 (23, 24) and complement. In parallel experi-
ments, this treatment lysed plastic-adherent human peripheral blood mononu-
clear cells (data not shown). HSVSMC were treated with complement, with or
without preincubation with anti-Mo2, and exposed to LPS (1 /Ag/ml), a potent
stimulus for IL-1 production by monocytes. Exposure to anti-Mo2 and comple-
ment did not impair the ability of HSVSMC to produce IL-1 in response to LPS
when compared with the ability of cells exposed to complement alone (Table 1).
Similar results were found with rIL-la or rIL-1Q as IL-1 secretagogues (Table
I) . IL-10 mRNA levels were similar in both groups of cells (data not shown). The
data in Table I also show that concentrations of rIL-la or rIL-I# that are
equipotent in the thymocyte costimulation assay induce the release of approxi-
mately equal amounts of IL-1 activity from HSVSMC .
rIL-1-induced IL-1 Production Is Not Mediated via TNF Release.
￿
TNF induces
the production of IL-1 in vascular smooth muscle cells (13), and IL-1 may also
induce the release of TNF in some cell types. We therefore addressed the
possibility that rIL-1-induced IL-1 production by HSVSMC was mediated by the
induction of TNF release. Cells were incubated with rIL-la (10 ng/ml) or rIL-
1,13 (100 ng/ml) for 24 h in the presence of rabbit anti-TNF antiserum or
nonimmune serum (both at 1:100 dilution). This anti-TNF antiserum neutralized
the cytotoxicity of rTNF for the murine fibroblast line L929 at a 1:400 dilution
(Ikejima, T., and C. A. Dinarello, unpublished data), and a 1 :200 dilution
detected 1 ng of rTNF in Western blots (data not shown). rIL-1-induced IL-1
release was not inhibited by the anti-TNF antiserum (Fig. 9). In addition, the
induction of IL-1,13 mRNA in HSVSMC incubated for 4 h with rIL-I# (100
ng/ml) was unaffected by anti-TNF antiserum at a concentration (1 :100 dilution)
IL-1 activity ([sH]TdR incorporation, dpm)
Exp. Treatment Unconditioned Conditioned medium
medium Without anti-Mo2 With anti-Mo2
1 LPS (1 14g/ml) 19,926 ± 1,499 34,691 ± 2,754 41,332 ± 3,392*
2 rIL-la (10 ng/ml) 52,363 ± 4,8721 130,556 f 7,949$ 148,525 ± 13,150**
rIL-I# (100 ng/ml) 45,994 ± 8,547 127,322 ± 3,857 148,047 t 10,296*
No addition 12,869 ± 1,523 14,090 t 757 15,779 t 4721326 VASCULAR SMOOTH MUSCLE CELL INTERLEUKIN 1 PRODUCTION
FIGURE 9 . Anti-TNF
￿
antiserum
does not inhibit rIL-1-induced IL-1
release from HSVSMC . Cells were
incubated for 24 h inDME/10%FCS
containing indomethacin (1 wg/ml)
andrIL-la (10 ng/ml) or rIL-1ß (100
ng/ml) alone, or with the addition of
either anti-TNF antiserum or non-
immune serum (1 :100 dilution) .
After 24 h, IL-1 activity in uncondi-
tioned (light bars) and conditioned
media (dark bars) (1 :1 dilution) was
measured. [sH]Thymidine incorpo-
ration in the presence of PHA alone
was 12,869 ± 1,523 dpm, and has
notbeen subtracted from the data .
that blocked TNF-induced IL-1ß mRNA production (data not shown) . These
data indicate that rIL-1-induced IL-1 production is not mediated via the release
of TNF.
Discussion
The manifold effects of IL-1 on vascular wall cells suggest an important role
for this mediator in blood vessel pathology . IL-1 induces morphologic changes
in cultured endothelial cells (38) and the production of procoagulant activity (4),
plasminogen activator inhibitor (5, 6), prostaglandins (7, 8), and platelet-activat-
ing factor (39) . In addition, IL-1 enhances adhesion to endothelial cells of all
classes of leukocytes studied (1-3) . Although the repertoire of endothelial cell
responses to IL-1 has been widely studied, the effect of this mediator on human
vascular smooth muscle cells has received scant attention . We report here the
surprising observation that IL-1 induces IL-1 gene expression in human vascular
smooth muscle . To our knowledge, this is the first definitive demonstration that
IL-1 may regulate its own synthesis and release in any cell type .
The threshold concentration for the production of IL-1 in HSVSMC by rIL-
10 was <1 ng/ml, which is at the low range of concentrations that elicit PGE2
production by human dermal fibroblasts and IL-2 generation from human T
cells (18) . Concentrations of rIL-la and rIL-lß that were equipotent in the
thymocyte costimulation assay induced similar amounts of IL-1 release (Table I
and Fig. 9) . rIL-1-induced IL-1 mRNA production and the extracellular release
of IL-1 began within 1 h of stimulation . Experiments with an antiserum that
neutralized the biological activity ofrTNF excluded a role for extracellular TNF
in the mediation of rIL-1-induced IL-1 production .
Our finding that smooth muscle cells exposed to monocyte-derived IL-1 for
short periods in vivo could respond by releasing further IL-1 may have important
implications for the pathogenesis of atherosclerosis and vasculitis . Human ath-
erosclerotic plaques contain smooth muscle cells, macrophages, andT cells in aWARNER ET AL.
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specific spatial distribution (40, 41). Smooth muscle cells in these plaques, but
not in normal arteries, express class 11 transplantation antigens, an indicator of
immune activation (42). Many ofthe Tlymphocytes in plaques express HLA/DR
antigens (40). These considerations indicate that the complicated human ather-
oma is not a static accumulation of lipid, calcium, and extracellular matrix, but
a site of active inflammatory and immunologic reaction. Our present findings
suggest novel humoral interactions between these cells that may contribute to
the formation ofthis localized lesion .
In cholesterol-fed animals, monocytes adhere to vascular endothelium, and
migrate into the developing atherosclerotic plaque (43-45). Vascular smooth
muscle cells and endothelial cells produce factors that are chemotactic for
monocytes (46, 47). Indeed, IL-1 itself isa potent monocyte chemoattractant (9),
and IL-1 secreted by vessel wall cells could recruit monocytes to areas of local
derangement. IL-1 produced locally by recruited monocytes, endothelial cells,
or smooth muscle cells could stimulate further IL-1 and PGE2 production by
vascular smooth muscle cells, withconcomitant alterations oflymphocyte, smooth
muscle, and endothelial cell functions. IL-1 causes T cells to produce IL-2 and
IFN-y, cytokines that activate T cells themselves and induce the expression of
IL-2 receptors and class 11 antigens on their surface (48). Activated T cells and
IFN-y also induce class II antigen expression on cultured endothelial cells and
smooth muscle cells (37, 49). Thus, local production of IL-1 in the vessel wall
may account for the expression of class II antigens on plaque cells observed in
vivo (40, 42). This study also shows that rIL-1,6 stimulates PGE2 release by
HSVSMC, in accordance with a previous report (8) that monocyte-derived IL-1
increased prostaglandin synthesis in human arterial smooth muscle cells. In
addition to modulating platelet function and vascular tone, prostaglandins reg-
ulate smooth muscle cell cholesterol metabolism (50), and may be chemoattract-
ant for leukocytes (46).
Our observation that IL-1 induces further IL-1 production from smooth
muscle cells also suggests a mechanism for the amplification and perpetuation of
vasculitis. Vascular smooth muscle cells from MRL/lpr mice that spontaneously
developagenetically determined autoimmune vasculitis, expressclassIIantigens,
and produce an IL-1-like factor (51). The vasculitic lesion is characterized by
perivascular cuffing and infiltration of mononuclear cells. Moyer and Reinisch
(51) suggested that smooth muscle cell-derived IL-1 stimulated the influx of
monocytes into these lesions. The potential role of IL-I in human vascular
inflammation in vivo is illustrated by recent studies (52) using an mAb, H4/18,
raised against IL-1-treated endothelial cells. IL-1 or TNF/cachectin induce
H4/18 binding sites on endothelial cells, but not on other cells tested. H4/18
does not bind normal endothelium in skin or other tissues. However, in human
delayed hypersensitivity reactions and other lesions associated with the presence
of activated lymphocytes and macrophages, microvascular endothelium does
bind H4/18 (53).
These examples show how IL-1 could be involved in the pathogenesis of
important pathologic processes involving the blood vessel wall. The common
ability ofboth vascular endothelial cells and smooth muscle cells to secrete IL-1,
and the stimulation of IL-1 synthesis and release by IL-1 itself reported here1328 VASCULAR SMOOTH MUSCLE CELL INTERLEUKIN I PRODUCTION
may thus be a crucial factor in the initiation, maintenance, and propagation of
these pathologic processes in vivo.
Summary
The recognition that cells of the vascular wall can secrete cytokines such as
IL-1 suggests new mechanisms for initiating or sustaining inflammatory responses
in blood vessels. We report that purified human monocyte-derived IL-I or
recombinant human IL-I (rIL-10 and rIL-la) induce cultured human smooth
muscle cells derived from veins or arteries to synthesize IL-10 mRNA and
produce and release biologically active IL-I . AL-10 also stimulated the produc-
tion of PGE2 by smooth muscle cells. Exposure to rIL-10 (1-100 ng/ml), or rIL-
la (0 .01-10 ng/ml) increased IL-10 mRNA levels within 30 min. Actinomycin
D (1 )ug/ml) prevented the induction of IL-10 mRNA by rIL-1. IL-la mRNA
was detected in SMC treated with cycloheximide (1 Ag/ml) and rIL-10, or
cycloheximide alone. rIL-la and rIL-10 produced maximal levels of IL-10
mRNA after 4 h, and intracellular IL-1 biological activity after 6 h of exposure.
Release of IL-I activity in the extracellular medium began after I h of incubation
with rIL-10 or rIL-la, and continued for up to 24 h. Anti-TNF antiserum that
neutralized the biological activity of rTNF did not affect rIL-1-induced produc-
tion of IL-10 mRNA or IL-1 release, suggesting that the release of TNF does
not mediate these processes. Several experimental approaches indicated that the
release of IL-1 by smooth muscle cells was not due to endotoxin contamination
of the IL-1 preparations. Anti-IL-1 antiserum blocked the induction of smooth
muscle cell IL-1 gene expression by rIL-10. Polymyxin B did not prevent IL-1-
induced IL-1 expression by these cells, but blocked the effect of endotoxin. Heat
treatment destroyed the stimulatory capacity of rIL-10, but did not affect the
ability of bacterial endotoxin to induce IL-1 expression. The production of IL-
I by human vascular smooth muscle cells was not due to contamination of the
cell cultures with blood monocytes, inasmuch as treatment with an antimonocyte
antibody (anti-Mo2) and complement did not alter IL-10 mRNA content or the
amount of IL-1 released from the cells in response to endotoxin, rIL-la, or rIL-
10. IL-1 production by smooth muscle cells, the most abundant cell type in the
blood vessel wall, may amplify and sustain local inflammatory responses in
vasculitis, allograft rejection, atherosclerosis, and vascular responses to injury or
pathogens in general.
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